A new antibiotic developed by a Flinders University researcher is being heralded as a breakthrough in the war against a drug resistant superbug.

Bacteria are winning the fight against antibiotics as they evolve to fight off traditional treatments, threatening decades of advancements in modern medicine, with predictions they will kill over 10 million people by 2050.

The scientific development of new, effective and safe antibiotics is crucial in addressing the ever-growing threat posed by drug resistant bacteria around the world.

Clostridium difficile infection (CDI) is a potentially deadly infection in the large intestine most common in people who need to take antibiotics for a long period of time, particularly in Australia's ageing population.

Dr Ramiz Boulos, adjunct research associate at Flinders University and CEO of Boulos & Cooper Pharmaceuticsals, says the fact CDI is becoming resistant to traditional antibiotics is alarming and highlights the need to develop more effective treatments.

"Cases of CDI disease are rising and the strains are becoming more lethal. If there is an imbalance in your intestines it can begin to grow and release toxins that attack the lining of the intestines which leads to symptoms," says Dr Boulos.

Over the past ten years, various strains of C. difficile have emerged, and are associated with outbreaks of severe infections worldwide. One particular strain is easily transmitted between people and has been responsible for large outbreaks in hospitals in the United States and Europe.

"It's concerning when you consider CDI is one of the most common infections acquired during hospital visits in the Western hemisphere, and the most likely cause of diarrhea for patients and staff in hospitals."

But when doses of a new antibiotic called Ramizol were given to hamsters infected with a lethal dose of the bacteria, a significant proportion of hamsters survived the infection.

In a recent safety study in rats evaluating the effect of repeated exposure of the antibiotic, no rats experienced serious side effects or changes in weight.

"Our research indicates Ramizol is an extremely well-tolerated antibiotic in rats, with good microbiology and antioxidant properties. It also has high chemical stability and is scalable because of the low cost of manufacturing, which could make it a viable treatment option."

Forty-eight rats were given a high dose of a new class of antibiotic for 14 days to assess its safety.

The research, which was undertaken jointly by Boulos & Cooper Pharmaceuticals, US- based Product Safety Labs and ToxStrategies and Flinders University was recently published in journal Scientific Reports.

"We are pleased with these results for two reasons. Firstly, we were able to give the rats a very high dose without mortalities or side effects,"

"Additionally, there were no changes in mean body weight, weight gain, food consumption or food efficiency for male and female rats attributable to Ramizol."

"We believe Ramizol has the potential to be the standard of care for treating CDI and has the potential to be a blockbuster drug."

Story Source:

Materials provided by Flinders University. Note: Content may be edited for style and length.

Journal Reference:

Katherine Sibley, Jayson Chen, Lee Koetzner, Odete Mendes, Amy Kimzey, Janice Lansita, Ramiz A. Boulos. A 14-day repeat dose oral gavage range-finding study of a first-in-class CDI investigational antibiotic, in rats. Scientific Reports, 2019; 9 (1) DOI: 10.1038/s41598-018-36690-9

Cite This Page:

MLA
APA
Chicago

Flinders University. "Fighting deadly drug resistant bacteria in intestines with new antibiotic: A new antibiotic is being heralded as a breakthrough in the war against a superbug." ScienceDaily. ScienceDaily, 18 January 2019. <www.sciencedaily.com/releases/2019/01/190118122954.htm>.

RELATED TOPICS
Health & Medicine
Infectious Diseases
Pharmaceuticals
Pharmacology
Today's Healthcare
Plants & Animals
Bacteria
Microbes and More
Extreme Survival
Microbiology

advertisement

RELATED TERMS
Salmonella infection
Urinary tract infection
Tuberculosis
Gastroenteritis
Hookworm
Tetanus
Sexually transmitted disease
Obstructive sleep apnea

RELATED STORIES
Routinely Prescribed Antibiotic May Not Be Best for Treating Severe C. Diff Infections
Feb. 6, 2017 — Over the past two decades there has been a sharp rise in the number and severity of infections caused by the bacteria Clostridium difficile. Scientists report that patients with a severe C. diff ... read more
Treatment Reduces Risk of Recurrence of C. Difficile Infection
May 5, 2015 — Among patients with Clostridium difficile infection (CDI) who recovered following standard treatment with the antibiotics metronidazole or vancomycin, oral administration of spores of a strain of C. ... read more
C. Difficile Doubles Hospital Readmission Rates, Lengths of Stay
Mar. 27, 2015 — Patients with Clostridium difficile infection (CDI) are twice as likely to be readmitted to the hospital as patients without the deadly diarrheal infection, according to a new ... read more
C. Difficile Epidemic Should Concern Not Only Hospital Patients but People at Home
June 16, 2014 — Without proper infection prevention in hospitals, and now homes, the Clostridium difficile bacteria poses a major health threat, cautions an infection control researcher. While mainly a concern in ... read more
FROM AROUND THE WEB
Below are relevant articles that may interest you. ScienceDaily shares links with scholarly publications in the TrendMD network and earns revenue from third-party advertisers, where indicated.

GenePOC C. Diff Test Receives FDA Approval
360Dx
New Technologies, Regulatory Approvals Highlight Antimicrobial Resistance Testing in 2018
Leo O'Connor, 360Dx
ID Genomics Launches Consortium to Improve Infectious Disease Diagnostics, Antibiotic Treatment
360Dx
Effect of 5-day Nitrofurantoin vs single-dose fosfomycin on clinical resolution of uncomplicated lower urinary tract infection in women a randomized clinical trial
JAMA - Journal of the American Medical Association

ID Genomics' Genetic Fingerprinting Technology Detects Superbug Along a Path to Apply for Regulatory Clearance
Leo O'Connor, 360Dx
Novobiocin Enhances Polymyxin Activity by Stimulating Lipopolysaccharide Transport
Journal of the American Chemical Society
NIST Scientists Measure Cell Mechanical Activity to Determine Antibiotic Efficacy, Resistance
360Dx
Linear Diagnostics Developing Microfluidic Cartridge to Detect Bacteria, Antibiotic Resistance
John Gilmore, 360Dx

Powered by
advertisement
Most Popular
this week
PLANTS & ANIMALS
Body-Painting Protects Against Bloodsucking Insects
New Houseplant Can Clean Your Home's Air
Fossil Deposit Is Much Richer Than Expected
EARTH & CLIMATE
Nepal Earthquake: Waiting for the Complete Rupture
Oceans Are Warming Even Faster Than Previously Thought
Antarctica Losing Six Times More Ice Mass Annually Now Than 40 Years Ago
FOSSILS & RUINS
Artificial Intelligence Applied to the Genome Identifies an Unknown Human Ancestor
Boy Or Girl? It's In The Father's Genes
Scientists Find Increase in Asteroid Impacts on Ancient Earth by Studying the Moon
advertisement